Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vaccine for preventing brucellosis by means of ophthalmic drug delivery

A technology for brucellosis and ocular drug delivery, which is applied in the direction of antibacterial drugs and bacterial antigen components, and can solve problems such as bacteria excretion and pregnant cow abortion

Inactive Publication Date: 2015-11-18
QILU ANIMAL HEALTH PROD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a live brucellosis vaccine for ophthalmic administration, thereby solving the problem of persistent antibody production in cattle caused by routine subcutaneous injection of brucellosis live vaccines, abortion in pregnant cows, and in the milk of lactating cows. The problem of detoxification

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for preventing brucellosis by means of ophthalmic drug delivery
  • Vaccine for preventing brucellosis by means of ophthalmic drug delivery
  • Vaccine for preventing brucellosis by means of ophthalmic drug delivery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] ——Comparison test of diluents of live brucellosis vaccine

[0054] The vaccine is diluted with the following 4 kinds of diluents:

[0055] (1) Sterile physiological saline;

[0056] (2) Phosphate buffer;

[0057] (3) Sterile physiological saline containing color indicator;

[0058] (4) Phosphate buffer containing color indicator.

[0059] Trypsin is used in the diluted vaccine The agar plate was used to count viable bacteria (colony forming units, CFU). The vaccine was placed at room temperature, and samples were taken for 1 hour, 2 hours, 3 hours, 4 hours, and 5 hours respectively, and the viable bacteria were counted on a tryptic agar plate. The results are shown in Table 1.

[0060] Table 1 Counting results of live bacteria at different storage time

[0061]

[0062] The results in Table 1 show that the vaccine was diluted with the above 4 kinds of diluents and placed at room temperature for 4 hours. The number of live bacteria before the vaccine was placed and the number of l...

Embodiment 2

[0064] ——Vaccine use

[0065] (1) Pour the diluent into the vaccine bottle, suspend and mix;

[0066] (2) Use an eye dropper (or syringe) to drip the vaccine into the orbit of the animal to be immunized, and the vaccine liquid does not flow out of the animal's orbit as a successful immunization.

Embodiment 3

[0068] -Immunization program

[0069] (1) One part of eye immunity;

[0070] (2) One dose of ocular immunization, one dose of immunization with the same method at intervals of 3-8 months;

[0071] (3) Subcutaneous injection of a standard dose (6×10 10 ~8×10 10 CFU), one dose of ocular immunization every 3 to 8 months;

[0072] (4) One dose of ocular immunization, with an interval of 3-8 months, subcutaneous injection of a standard dose (6×10 10 ~8×10 10 CFU).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a vaccine for preventing brucellosis by means of ophthalmic drug delivery. Through adoption of the vaccine for preventing brucellosis by means of ophthalmic drug delivery, the problems of continuous production of antibodies by immune cows, abortion of pregnant cows and bacterium excretion in adult cow milk due to conventional subcutaneous injection of a bacterium burgeri vaccine are solved.

Description

Technical field [0001] The invention relates to a vaccine used for ocular administration to prevent brucellosis, belonging to the field of veterinary biological products. Background technique [0002] Brucellosis, also known as brucellosis, is a zoonotic disease caused by Brucella, also known as Brucella (Bruce11aabortus). It is characterized by female animal abortion, infertility and male animal orchitis. OIE classifies it as a category B disease. Brucellosis is widely distributed around the world and can affect a variety of domestic animals, wild animals and humans. Brucella has the characteristics of extensive hosts, strong infectivity, and difficulty in curing after infection, which poses a serious threat to animal husbandry and human health. After a person is infected with Brucella, antibiotic treatment is needed for a long time, and it often leaves serious sequelae. In countries where brucellosis is endemic, the elimination of brucellosis has always been one of the most...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/10A61P31/04
Inventor 禚宝山鞠洪涛王蕾薛原张小军吴昊
Owner QILU ANIMAL HEALTH PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com